BRIEF-Abbvie And Remegen Announce Exclusive Licensing Agreement To Develop A Novel Bispecific Antibody For Advanced Solid Tumors

Reuters01-12

Jan 12 (Reuters) - RemeGen Co Ltd 688331.SS:

ABBVIE AND REMEGEN ANNOUNCE EXCLUSIVE LICENSING AGREEMENT TO DEVELOP A NOVEL BISPECIFIC ANTIBODY FOR ADVANCED SOLID TUMORS
ABBVIE: REMEGEN ELIGIBLE TO RECEIVE UP TO USD $4.95 BILLION IN AGGREGATE DEVELOPMENT, REGULATORY, AND COMMERCIAL MILESTONE PAYMENTS
ABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF UPTO $650 MILLION
ABBVIE: WILL RECEIVE EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE RC148 OUTSIDE OF GREATER CHINA TERRITORY
ABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF USD $650 MILLION

Source text: ID:nPn49sX0la

Further company coverage: 688331.SS

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602512082?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602512082","market":"nz","top_or_hot":-1,"title":"BRIEF-Abbvie And Remegen Announce Exclusive Licensing Agreement To Develop A Novel Bispecific Antibody For Advanced Solid Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Abbvie And Remegen Announce Exclusive Licensing Agreement To Develop A Novel Bispecific Antibody For Advanced Solid Tumors</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>RemeGen Co Ltd <span>688331.SS</span>:</p><ul><li><p>ABBVIE AND REMEGEN ANNOUNCE EXCLUSIVE LICENSING AGREEMENT TO DEVELOP A NOVEL BISPECIFIC ANTIBODY FOR ADVANCED SOLID TUMORS</p></li><li><p>ABBVIE: REMEGEN ELIGIBLE TO RECEIVE UP TO USD $4.95 BILLION IN AGGREGATE DEVELOPMENT, REGULATORY, AND COMMERCIAL MILESTONE PAYMENTS</p></li><li><p>ABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF UPTO $650 MILLION</p></li><li><p>ABBVIE: WILL RECEIVE EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE RC148 OUTSIDE OF GREATER CHINA TERRITORY</p></li><li><p>ABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF USD $650 MILLION</p></li></ul><p>Source text: <span>ID:nPn49sX0la</span></p><p>Further company coverage: <span>688331.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Abbvie And Remegen Announce Exclusive Licensing Agreement To Develop A Novel Bispecific Antibody For Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Abbvie And Remegen Announce Exclusive Licensing Agreement To Develop A Novel Bispecific Antibody For Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Abbvie And Remegen Announce Exclusive Licensing Agreement To Develop A Novel Bispecific Antibody For Advanced Solid Tumors</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>RemeGen Co Ltd <span>688331.SS</span>:</p><ul><li><p>ABBVIE AND REMEGEN ANNOUNCE EXCLUSIVE LICENSING AGREEMENT TO DEVELOP A NOVEL BISPECIFIC ANTIBODY FOR ADVANCED SOLID TUMORS</p></li><li><p>ABBVIE: REMEGEN ELIGIBLE TO RECEIVE UP TO USD $4.95 BILLION IN AGGREGATE DEVELOPMENT, REGULATORY, AND COMMERCIAL MILESTONE PAYMENTS</p></li><li><p>ABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF UPTO $650 MILLION</p></li><li><p>ABBVIE: WILL RECEIVE EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE RC148 OUTSIDE OF GREATER CHINA TERRITORY</p></li><li><p>ABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF USD $650 MILLION</p></li></ul><p>Source text: <span>ID:nPn49sX0la</span></p><p>Further company coverage: <span>688331.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2112291526.USD","symbol_name":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0CU:1","article_id":"2602512082","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602512082","pubTimestamp":1768221373,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Abbvie And Remegen Announce Exclusive Licensing Agreement To Develop A Novel Bispecific Antibody For Advanced Solid TumorsJan 12 (Reuters) - RemeGen Co Ltd 688331.SS:ABBVIE AND REMEGEN ANNOUNCE ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688331":"荣昌生物","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4588":"碎股","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","SG9999015978.USD":"利安颠覆性创新基金A","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","BK4559":"巴菲特持仓","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","ABBV":"艾伯维公司","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","BK4585":"ETF&股票定投概念","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK4139":"生物科技","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4533":"AQR资本管理(全球第二大对冲基金)","BK0239":"医药制造","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC"},"translate_title":"BRIEF-Abbvie和Remegen宣布达成独家许可协议，开发一种用于晚期实体瘤的新型双特异性抗体","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":0.9,"ABBV":0.9},"content_text":"BRIEF-Abbvie And Remegen Announce Exclusive Licensing Agreement To Develop A Novel Bispecific Antibody For Advanced Solid TumorsJan 12 (Reuters) - RemeGen Co Ltd 688331.SS:ABBVIE AND REMEGEN ANNOUNCE EXCLUSIVE LICENSING AGREEMENT TO DEVELOP A NOVEL BISPECIFIC ANTIBODY FOR ADVANCED SOLID TUMORSABBVIE: REMEGEN ELIGIBLE TO RECEIVE UP TO USD $4.95 BILLION IN AGGREGATE DEVELOPMENT, REGULATORY, AND COMMERCIAL MILESTONE PAYMENTSABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF UPTO $650 MILLIONABBVIE: WILL RECEIVE EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE RC148 OUTSIDE OF GREATER CHINA TERRITORYABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF USD $650 MILLIONSource text: ID:nPn49sX0laFurther company coverage: 688331.SS ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602512082","isCrawlerRequest":true}